5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

New pCPA Website & Available Data

April 7, 2020
-
Market Access News
-
Posted by MORSE - 2 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks.

Highlights of the pCPA activity in March are:

  • 5 products completed CADTH review, for a total of 16 files under consideration;
  • 2 products initiated pCPA negotiations, for a total of 29 active negotiations;
  • 3 negotiations completed for a total of 304 completed negotiations;
  • 3 negotiations closed, for a total of 51 closed negotiations; and
  • No files were closed without negotiation, for a total of 73 declined negotiations.

 

Files Under pCPA Consideration

5 new drug products received a CDEC recommendation or pERC notification to implement in March 2020, for a total of 16 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Darzalex Daratumumab Janssen Multiple Myeloma Conditional
Lokelma sodium zirconium cyclosilicate AstraZeneca Hyperkalemia, adults Do not reimburse
Monoferric Iron (III) Isomaltoside 1000 Pharmacosmos A/S Iron deficiency anemia Conditional
Onstryv Safinamide Valeo Parkinson’s disease Do not reimburse
Taltz ixekizumab Eli Lilly Ankylosing spondylitis Conditional

 

Negotiation Initiation

The pCPA initiated 2 new negotiations in March, for a total of 29 active negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Initiation Time to Initiate
Kanjinti Trastuzumab Amgen early breast cancer/metastatic breast cancer/metastatic gastric cancer N/A 24 Mar 20 N/A
Envarsus PA Tacrolimus Paladin prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients N/A 16 Mar 20 N/A

 

Signals Decoded:
 
March saw the pCPA initiate negotiations for the 4th trastuzumab biosimilar (Kanjinti), while Envarsus enters pCPA negotiations after being reviewed by INESSS; recommendation issued November 2019.

 

 

Completed

The pCPA completed 3 negotiations since the last update for a total of 304 completed negotiations.

 

Brand Name Generic Name Manufacturer Indication Initiation Close Date Duration
Triamcinolone Hexacetonide Triamcinolone Hexacetonide Medexus Rheumatoid Arthritis 22 Nov 19 31 Mar 20 130 days
Xalkori Crizotinib Pfizer ROS1-positive advanced NSCLC 27 Aug 19 20 Mar 20 206 days
Januvia Sitagliptin Merck Diabetes mellitus, Type 2 2 Nov 18 10 Mar 20 494 days

 

Signals Decoded:
 
The pCPA and Merck have renegotiated the Januvia agreement, after over 16 months of discussions.

 

Closed

The pCPA closed 3 negotiations since the last update for a total of 51 closed negotiations.

 

Brand Name Generic Name Manufacturer Indication Engagement Letter Close Date Duration
Orfadin Oral Suspension nitisinone Sobi Hereditary Tyrosinemia Type 1 August 9, 2019 March 30, 2020 234 days
Steglatro ertugliflozin Merck Diabetes Mellitus, Type 2 March 20, 2019 March 31, 2020 377 days
Segluromet ertugliflozin and metformin hydrochloride Merck Diabetes Mellitus, Type 2 March 20, 2019 March 31, 2020 377 days

 

 

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
April 2020 Update to The Canadian Reimbursement Trends & Timelines Report - Now Available
NEXT POST →
pCPA - The Beginning of a Period of Uncertainty?

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
New pCPA Website & Available Data